Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alnylam Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentations at Upcoming Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Planned CEO Leadership Transition
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Host Eighth Annual “RNAi Roundtable” Webcast Series
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
Alnylam Announces New Advances in ATTR Amyloidosis Program
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Tickers ALNY
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.